Characteristic | SLEDAI score | Test of significance | p | |
---|---|---|---|---|
Group 1 (low disease activity) (n = 20) | Group 2 (moderate to very high disease activity) (n = 30) | |||
Demographic and clinical characteristics | ||||
Age (years), M ± SD | 26.15 ± 8.86 | 27.53 ± 9.12 | t = −0.531 | 0.372 |
Residence, n (%) | ||||
Urban | 9 (45) | 17 (57) | χ2 = 0.654 | 0.419 |
Rural | 11 (55) | 13 (57) | ||
SLEDAI score | 1.90 ± 0.72 | 16.0 ± 2.28 | < 0.001* | |
Neuropsychiatric manifestations, n (%) | ||||
Headache | 7 (35) | 13 (43.3) | χ2 = 0.437 | 0.56 |
Psychosis | 6 (30) | 6 (20) | χ2 = 0.658 | 0.42 |
Seizures | 3 (15) | 3 (10) | χ2 = 284 | 0.67 |
Polyneuropathy | 4 (20) | 2 (6.7) | χ2 = 2.02 | 0.2 |
Acute confusional state | 0 (0) | 6 (12) | χ2 = 4.545 | 0.03* |
Cerebrovascular accidents | 0 (0) | 2 (6.7) | χ2 = 1.389 | 0.24 |
Psychiatric scores | ||||
HAM-D, n (%) | ||||
Negative | 11 (55) | 18 (60) | χ2 =2.524 | 0.28 |
Mild | 8 (40) | 7 (23.3) | ||
Moderate | 1 (5) | 5 (16.7) | ||
HARS, n (%) | ||||
Negative | 9 (45) | 17 (56.6) | χ2 = 1.427 | 0.49 |
Mild to moderate | 7 (35) | 5 (16.7) | ||
Moderate to severe | 4 (20) | 8 (26.7) | ||
MMSE, M ± SD | 29.35 ± 0.88 | 28.73 ± 1.59 | t = 1.574 | 0.12 |
W. logical memory, M ± SD | 15.65 ± 4 | 13.70 ± 5.91 | t = 1.290 | 0.20 |
W. digits forward, M ± SD | 4.55 ± 1.82 | 4.93 ± 1.41 | t = −0.837 | 0.41 |
W. digits backward, M ± SD | 2.60 ± 1.05 | 2.83 ± 1.42 | t = −0.630 | 0.67 |
Total Wechsler Memory Scale, M ± SD | 22.80 ± 5.11 | 21.47 ± 7.26 | t = 0.831 | 0.48 |
Cognition as whole, M ± SD | 52.15 ± 5.38 | 50.20 ± 8.09 | t = 0.521 | 0.35 |
Anti-ribosomal P protein antibody (units/ml), median (min–max) | 8.5 (2.5–46.3) | 17.55 (2.70–88.7) | MWT = −1.891 | 0.026* |
MRS measurements in the posterior cingulate gyrus, M ± SD | ||||
NAA/Cr | 1.71 ± 0.2 | 1.55 ± 0.24 | t = 2.531 | 0.015* |
Cho/Cr | 0.91 ± 0.19 | 1.02 ± 0.18 | t = −2.022 | 0.049* |
mI/Cr | 0.54 ± 0.1 | 0.53 ± 0.1 | t = 0.632 | 0.53 |